Tamoxifen for the prevention of breast cancer: no.

M. W. DeGregorio, J. U. Maenpaa, V. J. Wiebe

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

The tamoxifen chemoprevention trial in health women is ongoing in over 250 cancer treatment centers. The use of tamoxifen for the treatment of postmenopausal women with known breast cancer has been touted as a medical breakthrough by many physicians. However, the ongoing trial which enroll high-risk healthy women above the age of 34, has been controversial since its initiation in 1991. Congressional hearings, editorial, and statistical analyses concerning the scientific basis of the trial have emerged over the past year. This chapter presents the newest scientific facts, and speculates on the unknown risks of using tamoxifen as a chemopreventive in healthy women.

Original languageEnglish (US)
Pages (from-to)175-185
Number of pages11
JournalImportant advances in oncology
StatePublished - 1995

Fingerprint

Tamoxifen
Breast Neoplasms
Chemoprevention
Women's Health
Hearing
Physicians
Therapeutics
Neoplasms

ASJC Scopus subject areas

  • Medicine(all)

Cite this

DeGregorio, M. W., Maenpaa, J. U., & Wiebe, V. J. (1995). Tamoxifen for the prevention of breast cancer: no. Important advances in oncology, 175-185.

Tamoxifen for the prevention of breast cancer : no. / DeGregorio, M. W.; Maenpaa, J. U.; Wiebe, V. J.

In: Important advances in oncology, 1995, p. 175-185.

Research output: Contribution to journalArticle

DeGregorio, MW, Maenpaa, JU & Wiebe, VJ 1995, 'Tamoxifen for the prevention of breast cancer: no.', Important advances in oncology, pp. 175-185.
DeGregorio, M. W. ; Maenpaa, J. U. ; Wiebe, V. J. / Tamoxifen for the prevention of breast cancer : no. In: Important advances in oncology. 1995 ; pp. 175-185.
@article{a359eee8b2394aca965841b744d5301c,
title = "Tamoxifen for the prevention of breast cancer: no.",
abstract = "The tamoxifen chemoprevention trial in health women is ongoing in over 250 cancer treatment centers. The use of tamoxifen for the treatment of postmenopausal women with known breast cancer has been touted as a medical breakthrough by many physicians. However, the ongoing trial which enroll high-risk healthy women above the age of 34, has been controversial since its initiation in 1991. Congressional hearings, editorial, and statistical analyses concerning the scientific basis of the trial have emerged over the past year. This chapter presents the newest scientific facts, and speculates on the unknown risks of using tamoxifen as a chemopreventive in healthy women.",
author = "DeGregorio, {M. W.} and Maenpaa, {J. U.} and Wiebe, {V. J.}",
year = "1995",
language = "English (US)",
pages = "175--185",
journal = "Important advances in oncology",
issn = "0883-5896",
publisher = "Lippincott Williams and Wilkins",

}

TY - JOUR

T1 - Tamoxifen for the prevention of breast cancer

T2 - no.

AU - DeGregorio, M. W.

AU - Maenpaa, J. U.

AU - Wiebe, V. J.

PY - 1995

Y1 - 1995

N2 - The tamoxifen chemoprevention trial in health women is ongoing in over 250 cancer treatment centers. The use of tamoxifen for the treatment of postmenopausal women with known breast cancer has been touted as a medical breakthrough by many physicians. However, the ongoing trial which enroll high-risk healthy women above the age of 34, has been controversial since its initiation in 1991. Congressional hearings, editorial, and statistical analyses concerning the scientific basis of the trial have emerged over the past year. This chapter presents the newest scientific facts, and speculates on the unknown risks of using tamoxifen as a chemopreventive in healthy women.

AB - The tamoxifen chemoprevention trial in health women is ongoing in over 250 cancer treatment centers. The use of tamoxifen for the treatment of postmenopausal women with known breast cancer has been touted as a medical breakthrough by many physicians. However, the ongoing trial which enroll high-risk healthy women above the age of 34, has been controversial since its initiation in 1991. Congressional hearings, editorial, and statistical analyses concerning the scientific basis of the trial have emerged over the past year. This chapter presents the newest scientific facts, and speculates on the unknown risks of using tamoxifen as a chemopreventive in healthy women.

UR - http://www.scopus.com/inward/record.url?scp=0029198107&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029198107&partnerID=8YFLogxK

M3 - Article

C2 - 7672804

AN - SCOPUS:0029198107

SP - 175

EP - 185

JO - Important advances in oncology

JF - Important advances in oncology

SN - 0883-5896

ER -